Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …

Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …

Background The development of anti-HER2 antibody–drug conjugates opens new
therapeutic options for patients with breast cancer, including patients with low expression of …

Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has
resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs …

Background HER2 amplification has been identified in 2–3% of patients with colorectal
cancer, although there are currently no approved HER2-targeted therapies for colorectal …

Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

The development of anti-HER2 agents has been one of the most meaningful advancements
in the management of metastatic breast cancer, significantly improving survival outcomes …

Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–
25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the …